Heron shares surge on positive pain drug data

Shares of Redwood City, CA-based Heron Therapeutics shot up 20% on its release of positive data from its Phase II clinical study of HTX-011 for treating post-operative pain in patients undergoing bunionectomy. The biotech says that all primary and secondary endpoints were met in the study of their drug, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam. Release

Suggested Articles

Notable Labs is adding $40 million to its reserves as it scales up its capabilities with plans to take its platform worldwide.

Trefoil Therapeutics raised $28 million to push its regenerative treatment for corneal dystrophies toward the clinic.

The financing sets AM-Pharma up to advance in sepsis-associated acute kidney injury independently now Pfizer has turned down its option to buy.